Effect of GutGard in the Management ofHelicobacter pylori: A Randomized Double Blind Placebo Controlled Study

Author:

Puram Sreenivasulu1,Suh Hyung Chae2,Kim Seung Un3,Bethapudi Bharathi4,Joseph Joshua Allan4,Agarwal Amit4,Kudiganti Venkateswarlu5

Affiliation:

1. D2L Pharma Research Centre, Bangalore 560 037, India

2. NICS, Seoul 135-763, Republic of Korea

3. Korea Polytechnic University, Siheung-Si 429-793, Republic of Korea

4. Research and Development Centre, Natural Remedies, Plot No.5B, Veerasandra Indl. Area, 19th K.M. Stone, Hosur Road, Electronic City, Bangalore, Karnataka 560 100, India

5. Anasuya Ayurveda Centre, Bangalore 560 050, India

Abstract

A randomized, double blind placebo controlled study was conducted to evaluate the efficacy of GutGard (root extract ofGlycyrrhiza glabra) in the management ofHelicobacter pylori(H. pylori) gastric load. Participants diagnosed withH. pyloriinfection were randomly assigned to two groups to orally receive 150 mg of GutGard (n=55) or placebo (n=52) once daily for 60 days.H. pyloriinfection was assessed using13C-urea breath test (13C-UBT) at days 0, 30, and 60. Stool Antigen test (HpSA) was also performed on days 0, 30, and 60. Repeated measures of analysis of variance (RMANOVA), chi-square, and Fisher's exact probability tests were used to compare the treatment outcomes. A significant interaction effect between group and time (P=0.00) and significant difference in mean Delta Over Baseline (DOB) values between GutGard (n=50) and placebo (n=50) treated groups after intervention period were observed. On day 60, the results of HpSA test were negative in 28 subjects (56%) in GutGard treated group whereas in placebo treated group only 2 subjects (4%) showed negative response; the difference between the groups was statistically significant. On day 60, the results of13C-UBT were negative in 24 (48%) in GutGard treated group and the difference between the groups was statistically significant. The findings suggest GutGard is effective in the management ofH. pylori.

Funder

NICS Co., Republic of Korea

Publisher

Hindawi Limited

Subject

Complementary and alternative medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3